Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease.

Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease.

Sandhoff disease is a severe neurodegenerative glycosphingolipid (GSL) lysosomal storage disorder, currently without treatment options. One therapeutic approach under investigation is substrate reduction therapy (SRT). By partially inhibiting GSL biosynthesis, the impaired rate of GSL catabolism is...

ver descrição completa

Detalhes bibliográficos
Main Authors:	Andersson, U, Smith, D, Jeyakumar, M, Butters, T, Borja, M, Dwek, R, Platt, F
Formato:	Journal article
Idioma:	English
Publicado em:	2004

Registos relacionados

Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease
Por: Ulrika Andersson, et al.
Publicado em: (2004-08-01)

NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin.
Por: Jeyakumar, M, et al.
Publicado em: (2004)

N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo.
Por: Andersson, U, et al.
Publicado em: (2000)

N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal sandhoff diseased mice
Por: Baek, R, et al.
Publicado em: (2004)

N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice.
Por: Baek, R, et al.
Publicado em: (2008)

Substrate reduction therapy in mouse models of the glycosphingolipidoses.
Por: Platt, F, et al.
Publicado em: (2003)

Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation.
Por: Jeyakumar, M, et al.
Publicado em: (2001)

N-butyldeoxygalactonojirimycin reduces postnatal cerebellar ganglioside content in a mouse model of GM1 gangliosidosis
Por: Kasperzyk, J, et al.
Publicado em: (2004)

N-butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis.
Por: Kasperzyk, J, et al.
Publicado em: (2004)

Substrate reduction therapy reduces brain ganglioside GM2 in neonatal Sandhoff disease mice
Por: Baek, R, et al.
Publicado em: (2005)

MRS reveals additional hexose N-acetyl resonances in the brain of a mouse model for Sandhoff disease.
Por: Lowe, J, et al.
Publicado em: (2005)

Substrate reduction therapy in Sandhoff disease: Evidence for improvement in nervous function in patients treated with miglustat
Por: Lachmann, R, et al.
Publicado em: (2006)

Analysis of stored oligosaccharides in a mouse model of a glycolipid storage (Sandhoff) disease
Por: Awan, F, et al.
Publicado em: (2003)

Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis.
Por: Elliot-Smith, E, et al.
Publicado em: (2008)

Inhibition of calcium uptake via the sarco/endoplasmic reticulum Ca2+-ATPase in a mouse model of Sandhoff disease and prevention by treatment with N-butyldeoxynojirimycin.
Por: Pelled, D, et al.
Publicado em: (2003)

Beneficial effects of acetyl-DL-Leucine (ADLL) in a mouse model of Sandhoff disease
Por: Kaya, E, et al.
Publicado em: (2020)

New developments in treating glycosphingolipid storage diseases.
Por: Platt, F, et al.
Publicado em: (2005)

Substrate reduction therapy
Por: Platt, F, et al.
Publicado em: (2007)

Substrate reduction therapy.
Por: Platt, F, et al.
Publicado em: (2008)

Design, synthesis, and biological evaluation of enantiomeric beta-N-acetylhexosaminidase inhibitors LABNAc and DABNAc as potential agents against Tay-Sachs and Sandhoff disease.
Por: Rountree, J, et al.
Publicado em: (2009)

Restricted ketogenic diet enhances the therapeutic action of N-butyldeoxynojirimycin towards brain GM2 accumulation in adult Sandhoff disease mice.
Por: Denny, C, et al.
Publicado em: (2010)

Infantile Sandhoff's disease
Por: K Sass, et al.
Publicado em: (2009-08-01)

Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis.
Por: Jeyakumar, M, et al.
Publicado em: (2002)

Storage solutions: treating lysosomal disorders of the brain.
Por: Jeyakumar, M, et al.
Publicado em: (2005)

An inducible mouse model of late onset Tay-Sachs disease.
Por: Jeyakumar, M, et al.
Publicado em: (2002)

Circadian profiling in two mouse models of lysosomal storage disorders; Niemann Pick type-C and Sandhoff disease.
Por: Richardson, K, et al.
Publicado em: (2016)

Efficacy of a Bicistronic Vector for Correction of Sandhoff Disease in a Mouse Model
Por: Evan Woodley, et al.
Publicado em: (2019-03-01)

Dysregulation of the NLRP3 Inflammasome and Promotion of Disease by IL-1β in a Murine Model of Sandhoff Disease
Por: Nick Platt, et al.
Publicado em: (2025-01-01)

Glycosphingolipid storage leads to the enhanced degradation of the B cell receptor in Sandhoff disease mice.
Por: te Vruchte, D, et al.
Publicado em: (2010)

An Inducible Mouse Model of Late Onset Tay–Sachs Disease
Por: Mylvaganam Jeyakumar, et al.
Publicado em: (2002-08-01)

Inhibition of glycogen breakdown by imino sugars in vitro and in vivo.
Por: Andersson, U, et al.
Publicado em: (2004)

Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy.
Por: Platt, F, et al.
Publicado em: (2001)

Pharmacological impairment of acrosome formation and sperm head morphogenesis reveals essential role of glycosphingolipids in spermiogenesis
Por: van der Spoel, A, et al.
Publicado em: (2002)

Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of Sandhoff disease.
Por: Karen M Ashe, et al.
Publicado em: (2011-01-01)

Decrease in Myelin-Associated Lipids Precedes Neuronal Loss and Glial Activation in the CNS of the Sandhoff Mouse as Determined by Metabolomics
Por: Emmanuelle Lecommandeur, et al.
Publicado em: (2020-12-01)

Membrane disruption and cytotoxicity of hydrophobic N-alkylated imino sugars is independent of the inhibition of protein and lipid glycosylation.
Por: Mellor, H, et al.
Publicado em: (2003)

Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis.
Por: Jeyakumar, M, et al.
Publicado em: (2003)

Impaired neural differentiation of induced pluripotent stem cells generated from a mouse model of Sandhoff disease.
Por: Yasuhiro Ogawa, et al.
Publicado em: (2013-01-01)

Abnormal differentiation of Sandhoff disease model mouse-derived multipotent stem cells toward a neural lineage.
Por: Yasuhiro Ogawa, et al.
Publicado em: (2017-01-01)

Glycosphingolipid profiling of tissues from mouse models of human lysosomal storage disorders
Por: Priestman, D, et al.
Publicado em: (2008)